Celeste Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth -86.47%
- Profit Growth -96.95%
- Ebitda -23.76%
- Net Worth -37.31%
- Total Assets -37.83%
About Celeste Life Sciences
Celeste Life Sciences Private Limited (CLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 November 2012 and has a history of 12 years and two months. Its registered office is in Delhi, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Sharma and Puja Sharma serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233DL2012PTC244947
-
Company No.
244947
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Nov 2012
-
Date of AGM
26 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Celeste Life Sciences Private Limited offer?
Celeste Life Sciences Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API Intermediate.
Who are the key members and board of directors at Celeste Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Sharma
|
Director | 25-Mar-2013 | Current |
|
Puja Sharma
|
Director | 16-Nov-2012 | Current |
Financial Performance of Celeste Life Sciences.
Celeste Life Sciences Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 86.47% decrease. The company also saw a substantial fall in profitability, with a 96.95% decrease in profit. The company's net worth observed a substantial decline by a decrease of 37.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Celeste Life Sciences?
In 2019, Celeste Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Cromene Life Sciences Private LimitedAnil Sharma is a mutual person
-
First Eduindia Limited
Puja Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Celeste Life Sciences?
Unlock and access historical data on people associated with Celeste Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Celeste Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Celeste Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
